Stefan Ries serves as CatalYm’s Chief Scientific Officer (CSO) and Head of the Munich Site. He brings the team over 20 years of experience in drug discovery and development with a focus on oncology. Before joining CatalYm, Stefan was CSO at Sibylla Biotech in Milan and CSO at DISCO Pharmaceuticals, where he was responsible for all R&D activities and strategy. Before his roles as CSO, he was a Venture Partner at Versant Ventures and served for 16 years at Hoffmann-La Roche in different positions with increasing responsibility, culminating in his position as Vice President, External Innovation, Oncology. Stefan has a PhD in Biochemistry from the University of Regensburg, Germany and completed his postdoctoral fellowship in the lab of Professor Frank McCormick at the NCI-designated Cancer Center of the University of California, San Francisco. He is a member of the American Association for Cancer Research.